Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers
Abstract
Rationale: N-methyl-D-aspartate receptor-mediated dissociatives and serotonergic hallucinogens are being increasingly used in therapeutic interventions that involve nonordinary states of consciousness and may represent a unique mental health paradigm wherein pharmacologically induced experiences are conducive to psychological well-being.
Objective: The aim of this study was to further understand how the phenomenological and health-promoting effects of high-dose dextromethorphan (DXM) compared to psilocybin in the same participants when administered under experimental conditions that are typical of therapeutic psychedelic trials.
Methods: Single, acute oral doses of DXM (400 mg/70 kg), psilocybin (10, 20, 30 mg/70 kg), and inactive placebo were administered under double-blind and psychologically supportive conditions to 20 healthy participants with histories of hallucinogen use. Ratings of personal meaning, spiritual significance, psychological challenge, and psychological insight attributed to acute drug experiences were assessed 7 h (at session end) and 1 week after each drug administration. Persisting psychological effects were assessed 1 week after each drug administration.
Results: High-dose DXM and psilocybin produced similar increases over placebo in ratings of drug experience that was predictive of psychological benefit at 1 week, even when expectancy effects were minimized. These effects tended to favor psilocybin in a dose-dependent manner and were limited by poor physical tolerability for DXM.
Conclusions: This analysis suggests the utility of exploring clinical applications of dissociatives that occur within the supportive contexts that are characteristic of psychedelic research and that prioritize the optimization of psychologically valuable drug experiences. This study was registered with ClinicalTrials.gov (NCT02033707).
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Schenberg EE. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front Pharmacol 2018;9:733.
2. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci 2010;11(9):642–651.
3. Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci 2021;42(11):929–942.
4. Johnston JN, Kadriu B, Allen J, et al. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 2023;226:109422.
5. Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 2010;5(8):e12412.
6. Carbonaro TM, Johnson MW, Hurwitz E, et al. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences. Psychopharmacology (Berl) 2018;235(2):521–534.
7. Hase A, Erdmann M, Limbach V, et al. Analysis of recreational psychedelic substance use experiences classified by substance. Psychopharmacology 2022;239(2):643–659.
8. Lepow L, Morishita H, Yehuda R. Critical period plasticity as a framework for psychedelic-assisted psychotherapy. Front Neurosci 2021;15:1–8.
9. Mathai DS, Mora V, Garcia-Romeu A. Toward synergies of ketamine and psychotherapy. Front Psychol 2022;13:868103.
10. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol 2017;8:974.
11. Roseman L, Haijen E, Idialu-Ikato K, et al. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J Psychopharmacol 2019;33(9):1076–1087.
12. Nayak S, Johnson MW. Psychedelics and psychotherapy. Pharmacopsychiatry 2021;54(4):167–175.
13. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, et al. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005;38(6):301–311.
14. Schmidt A, Kometer M, Bachmann R, et al. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl) 2013;225(1):227–239.
15. van Schalkwyk GI, Wilkinson ST, Davidson L, et al. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. J Affect Disord 2018;227:11–16.
16. Mathai DS, Meyer MJ, Storch EA, et al. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. J Affect Disord 2020;264:123–129.
17. Mathai DS, Nayak SM, Yaden DB, et al. Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology (Berl) 2023;240:827–836.
18. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006;187(3):268–283.
19. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl) 2011;218(4):649–665.
20. Millière R. Looking for the self: Phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution. Front Hum Neurosci 2017;11:1–22.
21. Hartogsohn I. The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Front Neurosci 2018;12:1–5.
22. Fischman LG. Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy. Neuropsychoanalysis 2019;21(2):53–78.
23. Amada N, Lea T, Letheby C, et al. Psychedelic experience and the narrative self: An exploratory qualitative study. J Conscious Stud 2020;27(9–10):6–33.
24. Gashi L, Sandberg S, Pedersen W. Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy 2021;87:102997.
25. Sumner R, Chacko E, McMilan R, et al. A qualitative and quantitative account of patient's experiences of ketamine and its antidepressant properties. J Psychopharmacol 2021;35(8):946–961.
26. Mollaahmetoglu O, Keeler J, Ashbullby K, et al. “This Is Something That Changed My Life”: A qualitative study of patients' experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry 2021;12:1–17.
27. Breeksema JJ, Niemeijer A, Kuin B, et al. Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study. Front Psychiatry 2022;13:948115.
28. Breeksema JJ, Niemeijer A, Kuin B, et al. Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: An interpretative phenomenological study. Psychopharmacology (Berl) 2023;240(7):1547–1560.
29. Marguilho M, Figueiredo I, Castro-Rodrigues P. A unified model of ketamine's dissociative and psychedelic properties. J Psychopharmacol 2023;37(1):14–32.
30. Carbonaro TM, Johnson MW, Griffiths RR. Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology 2020;237(8):2293–2304.
31. Barrett FS, Carbonaro TM, Hurwitz E, et al. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Effects on cognition. Psychopharmacology (Berl) 2018;235(10):2915–2927.
32. Johnson M, Richards W, Griffiths R. Human hallucinogen research: Guidelines for safety. J Psychopharmacol 2008;22(6):603–620.
33. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 1998;31 Suppl 2:80–84.
34. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3(2):77–101.
35. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20(1):37–46.
36. De Vries H, Elliott MN, Kanouse DE, et al. Using pooled kappa to summarize interrater agreement across many items. Field Methods 2008;20:272–282.
37. Kirch W, (ed). Pearson's Correlation Coefficient. In: Encyclopedia of Public Health. Springer Netherlands: Dordrecht; 2008; pp. 1090–1091.
38. Pearson ES, D'Agostino RB, Bowman KO. Tests for departure from normality: Comparison of powers. Biometrika 1977;64(2):231–246.
39. McHugh ML. Interrater reliability: The kappa statistic. Biochem Med (Zagreb) 2012;22(3):276–282.
40. van Elk M, Yaden DB. Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neurosci Biobehav Rev 2022;140:104793.
41. Iosifescu DV, Jones A, O'Gorman C, et al. Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry 2022;83(4):41226.
42. Bennett R, Yavorsky C, Bravo G. Ketamine for bipolar depression: Biochemical, psychotherapeutic, and psychedelic approaches. Front Psychiatry 2022;13:1–9.
43. Reissig CJ, Carter LP, Johnson MW,et al. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology (Berl) 2012;223(1):1–15.
44. Consumer Healthcare Products Association. Dextromethorphan: Briefing Book for the Meeting of the FDA Drug Safety and Risk Management Committee [Internet]; 2010. Available from: https://www.chpa.org/sites/default/files/media/docs/2020-10/Briefing-book-Dextromethorphan-09142010.pdf [Last accessed: May 31, 2023].
45. Silva AR, Dinis-Oliveira RJ. Pharmacokinetics and pharmacodynamics of dextromethorphan: Clinical and forensic aspects. Drug Metab Rev 2020;52(2):258–282.
46. Morris H, Wallach J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 2014;6(7–8):614–632.
47. Bowins BE. Therapeutic dissociation: Compartmentalization and absorption. Counsel Psychol Quart 2012;25(3):307–317.
48. Butler LD. Normative dissociation. Psychiatr Clin North Am 2006;29(1):45–62, viii.
49. Dell PF, O'Neil JA. Dissociation and the Dissociative Disorders: DSM-V and Beyond. Routledge: New York, NY; 2010; p. 899.
50. Seligman R, Kirmayer LJ. Dissociative experience and cultural neuroscience: Narrative, metaphor and mechanism. Cult Med Psychiatry 2008;32(1):31–64.
51. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry 2021;178(5):383–399.
52. Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 2020;25(7):1592–1603.
53. Kryst J, Kawalec P, Mitoraj AM, et al. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: A meta-analysis of randomized clinical trials. Pharmacol Rep 2020;72(3):543–562.
54. Mathai DS, McCathern AG, Guzick AG, et al. Parental attitudes toward use of ketamine in adolescent mood disorders and suicidality. J Child Adolesc Psychopharmacol 2021;31(8):553–561.
55. Aday JS, Heifets BD, Pratscher SD, et al. Great expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl) 2022;239(6):1989–2010.
56. Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 2014;7(3):157–164.
Information & Authors
Information
Published In
Copyright
Copyright 2023, Mary Ann Liebert, Inc., publishers.
History
Published online: 13 December 2023
Published in print: December 2023
Published ahead of print: 30 August 2023
Authors
Authors' Contributions
D.S.M.: conceptualization, formal analysis, methodology, writing—original draft; Samantha Hilbert: formal analysis, methodology, software, validation, visualization, writing—review and editing; N.D.S.: data curation, resources, software, writing—review and editing; J.C.S.: methodology, writing—review and editing; R.R.G.: conceptualization, funding acquisition, investigation, methodology, project administration, resources, writing—review and editing; A.G.-R.: conceptualization, formal analysis, methodology, project administration, supervision, writing—review and editing.
Author Disclosure Statement
J.C.S. has received research funding from the Canopy Growth Corporation. A.G.-R. serves as a paid scientific advisor to Innerwell and NeonMind Biosciences. R.R.G. is on the board of directors of the Heffter Research Institute. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding Information
Conduct of this research was funded by NIH grants R01DA03889 and T32 DA07209, the Heffter Research Institute, and the Center for Psychedelic and Consciousness Research supported by Tim Ferriss, Matt Mullenweg, Craig Nerenberg, Blake Mycoskie, and the Steven and Alexandra Cohen Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.